Market Overview

LabCorp Clinical Trials Enters 5-Year Agreement with Bristol-Myers Squibb


Laboratory Corporation of America Holdings
(NYSE: LH) today announced that LabCorp Clinical Trials has been selected
as a preferred provider for full-service global central laboratory
services and biomarker testing by Bristol-Myers Squibb Company (NYSE: BMY).

The five-year agreement builds on a long-standing partnership between
the two companies during which LabCorp's global central lab, biomarker
and specialty testing capabilities have supported various Bristol-Myers
Squibb early and late-stage clinical development programs.

“We are excited to expand our relationship with Bristol-Myers Squibb to
provide a more flexible and integrated approach to laboratory testing
services in support of their innovative clinical development pipeline,”
said Dr. Mark Brecher, LabCorp's Chief Medical Officer.

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (BMY + LH)

View Comments and Join the Discussion!

Benzinga Market Primer: Monday, April 1

Acacia Subsidiary Enters into License Agreement with Ventyx USA